APA (7th ed.) Citation

Hu, Z., Jin, W., Lou, S., & Zhang, L. (2025). Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China. Renal Failure, 47(1), 1. https://doi.org/10.1080/0886022X.2025.2578413

Chicago Style (17th ed.) Citation

Hu, Zhengqiang, Wei Jin, Shengying Lou, and Lejun Zhang. "Cost-effectiveness of Combining Finerenone and Sodium-glucose Cotransporter 2 Inhibitors with Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China." Renal Failure 47, no. 1 (2025): 1. https://doi.org/10.1080/0886022X.2025.2578413.

MLA (9th ed.) Citation

Hu, Zhengqiang, et al. "Cost-effectiveness of Combining Finerenone and Sodium-glucose Cotransporter 2 Inhibitors with Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China." Renal Failure, vol. 47, no. 1, 2025, p. 1, https://doi.org/10.1080/0886022X.2025.2578413.